S 1039

South Carolina General Assembly
126th Session, 2025-2026
Bill 1039
Indicates Matter Stricken
Indicates New Matter
(Text matches printed bills. Document has been reformatted to meet World Wide Web specifications.)
A bill
TO AMEND THE SOUTH CAROLINA CODE OF LAWS BY AMENDING
SECTION 44-53-190, RELATING TO SCHEDULE I SUBSTANCES, SO AS TO ADD SUBSTITUTED
TRYPTAMINES TO THE LIST OF SCHEDULE I SUBSTANCES.
Be it enacted by the
General Assembly of the State of South Carolina:
SECTION 1.  Section 44-53-190(D) of the S.C. Code is amended to
read:
    (D) Any material, compound, mixture,
or preparation which contains any quantity of the following hallucinogenic
substances, their salts, isomers, and salts of isomers, unless specifically
excepted, whenever the existence of such salts, isomers, and salts of isomers
is possible within the specific chemical designation:
       1. 3,4-methylenedioxy
amphetamine
       2. 5-methoxy-3,4-methylenedioxy
amphetamine
       3. 3,4-methylenedioxymethamphetamine
(MDMA)
       4. 3,4,5-trimethoxy
amphetamine
       5. Bufotenine
       6. Diethyltryptamine
(DET)
       7. Dimethyltryptamine
(DMT)
       8.5. 4-methyl-2,5-dimethoxyamphetamine
(STP)
       9.6. Ibogaine
       10.7. Lysergic acid
diethylamide (LSD)
       11.8. Marijuana
       12.9. Mescaline
       13.10. Peyote
       14.11. N-ethyl-3-piperidyl
benzilate
       15.12. N-methyl-3-piperidyl
benzilate
       16.13. Psilocybin
       17.14. Psilocyn
       18.15. Tetrahydrocannabinol
(THC)
       19.16. 2,5-dimethoxyamphetamine
       20.17. 4-bromo-2,5-dimethoxyamphetamine
       21.18. 4-Methoxyamphetamine
       22.19. Thiophene analog of
phencyclidine
       23.20. Parahexyl
       24.21. Synthetic
cannabinoids.-Any material, compound, mixture, or preparation that is not
listed as a controlled substance in Schedule I through V, is not an
FDA-approved drug, and contains any quantity of the following substances, their
salts, isomers (whether optical, positional, or geometric), homologues, and
salts of isomers and homologues, unless specifically excepted, whenever the
existence of these salts, isomers, homologues, and salts of isomers and
homologues is possible within the specific chemical designation:
  a. Naphthoylindoles.
Any compound containing a 3-(1-naphthoyl)indole structure with substitution at
the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the naphthyl ring to any
extent. Including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073,
JWH-081, JWH-122, JWH-200, JWH-210, JWH-398, AM-2201, WIN 55-212, AM-2201 (C1
analog), AM-1220.
  b. Naphthylmethylindoles.
Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with
substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the
indole ring to any extent and whether or not substituted in the naphthyl ring
to any extent.
  c. Naphthoylpyrroles.
Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at
the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole
ring to any extent and whether or not substituted in the naphthyl ring to any
extent. Including, but not limited to, JWH-307, JWH-370, JWH-176.
  d. Naphthylmethylindenes.
Any compound containing a naphthylideneindene structure with substitution at
the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene
ring to any extent and whether or not substituted in the naphthyl ring to any
extent.
  e. Phenylacetylindoles.
Any compound containing a 3-phenylacetylindole structure with substitution at
the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the phenyl ring to any
extent. Including, but not limited to, SR-18, RCS-8, JWH-203, JWH-250, JWH-251.
  f. Cyclohexylphenols.
Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with
substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl
ring to any extent. Including, but not limited to, CP 47,497 (and homologues),
cannabicyclohexanol, CP-55, 940.
  g. Benzoylindoles.
Any compound containing a 3-(benzoyl)indole structure with substitution at the
nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the phenyl ring to any
extent. Including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4,
AM-630, AM-1241, AM-2233.
  h. 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo
[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-napthalenylmethanone (WIN 55,212-2).
  i. 9-(hydroxymethyl)-6,6-dimethy
l-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol 7370
(HU-210, HU-211).
  j. Adamantoylindoles.
Any compound containing a 3-(1-adamantoyl)indole structure with substitution at
the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the adamantyl ring system
to any extent.
       22.
Substituted Tryptamines. Any material, compound, mixture, or preparation
containing a 2-(1H-indol-3-yl)ethanamine, for example tryptamine, structure
with or without mono- or di-substitution of the amine nitrogen with alkyl or
alkenyl groups, or by inclusion of the amino nitrogen atom in a cyclic
structure, whether or not substituted at the alpha position with an alkyl
group, whether or not substituted on the indole ring to any extent with any
alkyl, alkoxy, halo, hydroxyl, or acetoxy groups, including, but not limited
to:
  a. Bufotenine,
  b. DET (Diethyltryptamine),
  c. DMT (Dimethyltryptamine),
  d. Methyltryptamine,
  e. 5-MeO-DMT (5-Methoxy-N,N,Dimethyltryptamine),
  f. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine),
  g. MET (N-Methyl-N-ethyltryptamine),
  h. DALT (N,N-Diallyltryptamine),
  i. EiPT (N-Ethyl-N-isopropyltryptamine),
  j. MiPT (N-Methyl-N-isopropyltryptamine),
  k. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine),
  l. 5-Hydroxy-N-methyltryptamine,
  m. 5-MeO-MiPT
(5-Methoxy-N-methyl-N-isopropyltryptamine),
  n. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine),
  o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine),
  p. DiPT (N,N-Diisopropyltryptamine),
  q. DPT (N,N-Dipropyltryptamine),
  r. 4-Hydroxy-DiPT
(4-Hydroxy-N,N-diisopropyltryptamine),
  s. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine),
  t. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine),
  u. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine),
  v. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine),
  x. 4-Hydroxy-MET
(4-Hydroxy-N-methyl-N-ethyltryptamine),
  y. 4-Hydroxy-MiPT
(4-Hydroxy-N-methyl-N-isopropyltryptamine),
  z. Methyl-alpha-ethyltryptamine,
  aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
  bb. 6-MeO-DMT (6-methoxy-N,N-dimethyltryptamine),
  cc. 5-OH-DMT (5-hydroxy-N,N-dimethyltryptamine),
  dd. 4-AcO-DET (4-Acetoxy-N,N-diethyltryptamine).
SECTION 2.  This act takes effect upon approval
by the Governor.
----XX----
This web page was last updated on March 19, 2026 at 11:38 AM